이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
CSPC Pharmaceutical Group 관리
관리 기준 확인 2/4
CSPC Pharmaceutical Group's CEO는 Cuilong Zhang, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 CN¥ 13.47M, 5.1% 로 구성됩니다. 5.1% 급여 및 94.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 26.92M 가치에 해당하는 회사 주식의 0.034% 직접 소유합니다. 26.92M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 7.3 년입니다.
주요 정보
Cuilong Zhang
최고 경영자
CN¥13.5m
총 보상
| CEO 급여 비율 | 5.1% |
| CEO 임기 | 2.2yrs |
| CEO 소유권 | 0.03% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 7.3yrs |
최근 관리 업데이트
Recent updates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price
Oct 18CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Sep 15CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10
Aug 26CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥6b |
| Dec 31 2023 | CN¥13m | CN¥693k | CN¥6b |
| Sep 30 2023 | n/a | n/a | CN¥6b |
| Jun 30 2023 | n/a | n/a | CN¥6b |
| Mar 31 2023 | n/a | n/a | CN¥6b |
| Dec 31 2022 | CN¥11m | CN¥693k | CN¥6b |
| Sep 30 2022 | n/a | n/a | CN¥6b |
| Jun 30 2022 | n/a | n/a | CN¥6b |
| Mar 31 2022 | n/a | n/a | CN¥6b |
| Dec 31 2021 | CN¥9m | CN¥693k | CN¥6b |
| Sep 30 2021 | n/a | n/a | CN¥6b |
| Jun 30 2021 | n/a | n/a | CN¥6b |
| Mar 31 2021 | n/a | n/a | CN¥5b |
| Dec 31 2020 | CN¥9m | CN¥693k | CN¥5b |
| Sep 30 2020 | n/a | n/a | CN¥4b |
| Jun 30 2020 | n/a | n/a | CN¥4b |
| Mar 31 2020 | n/a | n/a | CN¥4b |
| Dec 31 2019 | CN¥7m | CN¥693k | CN¥4b |
| Sep 30 2019 | n/a | n/a | CN¥4b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥3b |
| Dec 31 2018 | CN¥4m | CN¥298k | CN¥3b |
보상 대 시장: Cuilong 의 총 보상 ($USD 1.86M )은 Hong Kong 시장( $USD 891.29K ).
보상과 수익: Cuilong 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.
CEO
Cuilong Zhang (55 yo)
2.2yrs
테뉴어
CN¥13,472,000
보상
Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 27.3yrs | CN¥26.68m | 23.78% CN¥ 17.4b | |
| Vice-Chairman & CEO | 2.2yrs | CN¥13.47m | 0.034% CN¥ 24.8m | |
| Executive Director & Chief Scientist | 6.6yrs | CN¥9.42m | 0.038% CN¥ 27.9m | |
| Executive Director | no data | CN¥4.92m | 0.013% CN¥ 9.3m | |
| Executive Director | no data | CN¥5.74m | 0.013% CN¥ 9.3m | |
| Executive Director | no data | CN¥4.90m | 0.013% CN¥ 9.3m | |
| Executive Director | no data | CN¥4.02m | 0.024% CN¥ 17.4m | |
| Group Executive President | no data | 데이터 없음 | 데이터 없음 | |
| Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Company Secretary | 3.5yrs | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 관리: 1093 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman | 27.3yrs | CN¥26.68m | 23.78% CN¥ 17.4b | |
| Vice-Chairman & CEO | 6yrs | CN¥13.47m | 0.034% CN¥ 24.8m | |
| Executive Director & Chief Scientist | 6.6yrs | CN¥9.42m | 0.038% CN¥ 27.9m | |
| Executive Director | 17.8yrs | CN¥4.92m | 0.013% CN¥ 9.3m | |
| Executive Director | 13.8yrs | CN¥5.74m | 0.013% CN¥ 9.3m | |
| Executive Director | 12.5yrs | CN¥4.90m | 0.013% CN¥ 9.3m | |
| Executive Director | 3.7yrs | CN¥4.02m | 0.024% CN¥ 17.4m | |
| Group Executive President | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 3.5yrs | CN¥340.00k | 데이터 없음 | |
| Independent Non-Executive Director | 11.6yrs | CN¥142.00k | 데이터 없음 | |
| Independent Non-Executive Director | 8.1yrs | CN¥142.00k | 데이터 없음 |
7.3yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 이사회: 1093 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.